Koers Curis, Inc. Nasdaq
Aandelen
US2312691015
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 8,78 mln. 8,09 mln. | Omzet 2025 * | 8,8 mln. 8,1 mln. | Marktkapitalisatie | 62,01 mln. 57,12 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -48 mln. -44,22 mln. | Nettowinst (verlies) 2025 * | -53 mln. -48,83 mln. | EV/omzet 2024 * | 7,06 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 7,05 x |
K/w-verhouding 2024 * |
-1,71
x | K/w-verhouding 2025 * |
-2,29
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,82% |
Recentste transcriptie over Curis, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
James Dentzer
CEO | Chief Executive Officer | 57 | 29-03-16 |
Diantha Duvall
DFI | Director of Finance/CFO | 52 | 26-07-22 |
Chief Tech/Sci/R&D Officer | - | 03-01-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Kenneth Kaitin
BRD | Director/Board Member | 71 | 01-11-03 |
Martyn Greenacre
CHM | Chairman | 82 | 14-02-00 |
James Dentzer
CEO | Chief Executive Officer | 57 | 29-03-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+41,79% | 54,04 mld. | |
+45,77% | 41,96 mld. | |
-0,56% | 41,92 mld. | |
-7,20% | 28,35 mld. | |
+12,59% | 26,35 mld. | |
-21,51% | 19 mld. | |
+6,92% | 13 mld. | |
+29,60% | 12,28 mld. | |
+24,91% | 12,19 mld. |